Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telithromycin vs Cefuroxime in Children with Acute Otitis Media
NCT00174811Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jun 2005
- Primary completion
- Jun 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of telithromycin in acute otitis media (AOM) (2 arms), sponsored by Sanofi. Primary endpoint: Clinical cure at the posttherapy/test-of-cure (TOC) Visit 3. Started Jun 2005; status: terminated.
02
Drugs
telithromycin
03
Conditions
acute otitis media (AOM)
Beyond the preview
Go deeper on NCT00174811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174811.